Sertraline in the treatment of depressive disorders in patients with Parkinson’s disease (original) (raw)
Dooneief G, Mirabello E, Bell K et al (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 49:305–307 PubMedCAS Google Scholar
Richard IH (2000) Depression in Parkinson’s disease. Curr Treat Options Neurol 2:263–274 ArticlePubMed Google Scholar
McDonald WM, Richard IH, Delong MR (2003) Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 54:363–375 ArticlePubMed Google Scholar
Behari M, Srivastava AK, Pandey RM (2005) Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord 11:221–226 ArticlePubMedCAS Google Scholar
Okun MS, Watt RL (2002) Depression associated with Parkinson’s disease: clinical features and treatment. Neurology 58[4 Suppl 1]:S63–70 PubMed Google Scholar
Yamamoto M (2001) Depression in Parkinson’s disease: its prevalence, diagnosis and neurochemical background. J Neurol 248[Suppl 3]:5–11 Google Scholar
Sawabini KA, Watts RL (2004) Treatment of depression in Parkinson’s disease. Parkinsonism Relat Disord 10:S37–S41 ArticlePubMed Google Scholar
Erdal KJ (2001) Depressive symptom patterns in patients with Parkinson’s disease and other older adults. J Clin Psychol 57:1559–1569 ArticlePubMedCAS Google Scholar
Goldestein BJ, Goodnich PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12[Suppl B]:S55–S87 Google Scholar
Rampello L, Chiechio R, Raffaele R et al (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin Neuropharmacol 25:21–24 ArticlePubMedCAS Google Scholar
Tesei S, Antonini A, Canesi M et al (2000) Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 15:986–989 ArticlePubMedCAS Google Scholar
Devanand DP, Pelton GH, Marston K et al (2003) Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 18:123–130 ArticlePubMedCAS Google Scholar
Hauser RA, Zesiewica TA (1997) Sertraline for the treatment of depression in Parkinson’s Disease. Mov Disord 12:756–759 ArticlePubMedCAS Google Scholar
Brady KT, Clary CM (2003) Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry 44:360–369 ArticlePubMed Google Scholar
Liebowitz MR, Demartinis NA, Weihs K et al (2003) Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785–792 ArticlePubMedCAS Google Scholar
Mauri MC, Fiorentini A, Cerveri G et al (2003) Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Hum Psychopharmacol 18:385–388 ArticlePubMedCAS Google Scholar
Dell’Agnello G, Ceravolo R, Nuti A et al (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227 ArticlePubMedCAS Google Scholar
Gelb JD, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39 ArticlePubMedCAS Google Scholar
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th Edn. American Psychiatric Association, Washington DC Google Scholar
Akdemir A, Turkcapar MK, Orsel SD et al (2001) Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 42:161–165 ArticlePubMedCAS Google Scholar
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134:382–389 ArticleCAS Google Scholar
Guy W (1976) ECDEU Assessment manual for psychopharmacology. Revised US Dept Health, Education and Welfare publication (ADM). National Institute of Mental Health, Rockville, MD, pp 76–338 Google Scholar
Kuopio AM, Marttila RJ, Helenius H et al (2000) The quality of life in Parkinson’s disease. Mov Disorder 15:216–223 ArticleCAS Google Scholar
Peto V, Jenkinson C, Fitzpatrick R (1998) PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 245[Suppl 1]:S10–S14 ArticlePubMed Google Scholar
Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord 21:1119–1122 ArticlePubMed Google Scholar
Gony M, Lapeyre-Mestre M, Montastruc JL(2003) French Network of regional Pharmacovigilance Centers. Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 26:142–145 ArticlePubMedCAS Google Scholar